Caption Management 13F: New $23M Stake in CORT

Caption Management recently established a brand-new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT). According to its latest Form 13F filing with the SEC for the period ending March 31, 2026, the institutional investor purchased 260,000 shares of the biopharmaceutical firm.

This newly initiated position carried a reported market value of $22.6 million at the close of the quarter. Because these filings are backward-looking and reflect holdings as of the reporting date, they do not necessarily represent Caption Management's current investment portfolio today. The firm is known for focusing on event-driven opportunities and relative value strategies, often taking tactical stakes in healthcare and biotechnology companies.

During Sunday trading, shares of Corcept Therapeutics were priced at $86.95. The stock has experienced wide swings over the past year, trading between a 52-week low of $28.66 and a 52-week high of $126.38. Its 50-day moving average sits at $108.60, while its longer-term 200-day moving average is $68.56. The biotechnology firm has a price-to-earnings ratio of 252.80, which is elevated due to recent product ramp-ups, though its forward P/E of 25.84 suggests expectations of stronger future profitability.

Double-Digit Revenue Growth

In its latest financial updates, Corcept showed significant business momentum. The company generated $830.8 million in revenue, which represents a 31.7% increase year-over-year. Corcept also recorded a net margin of 6.64% and a return on equity of 8.23%. The company's next earnings report is scheduled for release on November 4, 2026, when investors will look for updates on its commercial treatments and clinical trials.

Analysts Set New Price Targets

Wall Street firms have been active in revising their expectations for Corcept. On September 18, 2026, HC Wainwright & Co. reiterated its Buy rating on the stock with a $165.00 price target. Earlier, on July 30, 2026, Piper Sandler maintained an Overweight rating and substantially lifted its price target from $88.00 to $165.00. On that same day, Canaccord Genuity kept a Buy rating and bumped its target up to $161.00, while HC Wainwright maintained its Buy rating with a target of $165.00. Conversely, Wolfe Research downgraded the stock on July 27, 2026, to an Underperform rating with a $50.00 price target. Across five analysts, the consensus remains a Buy with a mean target price of $141.00.

Cushing's Syndrome and Cortisol Modulation

Corcept Therapeutics focuses on discovering and developing medications that treat severe metabolic, oncologic, and neurologic disorders. Its lead commercial product is Korlym, an oral medication approved to treat high blood sugar in patients with endogenous Cushing's syndrome. The company is also developing next-generation selective cortisol modulators, such as relacorilant and miricorilant, which are currently progressing through clinical trials.

What to Watch at Corcept Therapeutics Incorporated

Market observers will want to monitor how Caption Management manages this new position in upcoming quarters. Future regulatory filings will reveal whether the manager is building a larger long-term stake or treating Corcept as a short-term tactical trade. Investors should also pay close attention to the November 4, 2026, earnings release for further updates on Korlym sales and pipeline updates.